Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2020 Issues

In memoriam

February 2020—Herbert Derman, MD, CAP president from 1983 to 1985, died Dec. 18, 2019, seeking a remedy to his chronic heart failure. Dr. Derman was CAP vice president from 1981 to 1983 and a member of the Board of Governors from 1971 to 1980. He was the chair and a member of several CAP councils, committees, and commissions. Dr. Derman was named CAP Pathologist of the Year in 1986. He received the ASCP/CAP Pathology Continuing Medical Education award in 1974 and 1978 and the ASCP/CAP Joint Distinguished Service award in 1993.

Can machine learning algorithms predict lab values?

February 2020—At Massachusetts General Hospital, machine learning is being used in the laboratories to build next-level clinical decision support, and in the latest phase, it’s undergoing trial for use in predicting laboratory results. “I think this is the new paradigm for cost-effective laboratory medicine. This is an important way we’re going to change how we do business,” says Anand Dighe, MD, PhD, who spoke about machine learning techniques for labs during a CAP19 presentation last fall and in a recent interview with CAP TODAY.

Using microfluidics to isolate circulating leukemia cells

February 2020—Microfluidic assays are being used to isolate circulating leukemia cells and manage minimal residual disease in some patients with acute myeloid leukemia and B-cell/T-cell acute lymphoblastic leukemia. “There is a lot of popularity in liquid biopsies, but there’s still a lot of work to do,” said Steven A. Soper, PhD, foundation distinguished professor of chemistry, mechanical engineering, and bioengineering at the University of Kansas. Dr. Soper, who also holds a teaching appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, was a co-presenter with Sunitha Nagrath, PhD (see story, page 3), at the 2019 AMP annual meeting.

AP LIS panel: complexity, middleware, reports, AI

February 2020—Middleware, transmitting and consuming reports, and artificial intelligence are just some of what AP LIS roundtable panelists talked about in December with CAP TODAY publisher Bob McGonnagle. Members of the panel were pathologists Monica de Baca, MD, and Jeffrey Prichard, DO, Rick Callahan of NovoPath, David Liberman, MD, of Computer Trust, and Chad Meyers of Sunquest. Here is what they said.

Put It on the Board

Roche, Illumina partner to broaden access to genomic testing
February 2020—Roche has entered into a 15-year, nonexclusive partnership with Illumina to broaden the adoption of distributable next-generation-sequencing–based testing in oncology. The agreement brings together the capabilities of both companies to broaden adoption of NGS in cancer care. As part of the agreement, Illumina will grant Roche rights to develop and distribute in vitro diagnostic tests on Illumina’s NextSeq 550Dx system and on its future portfolio of diagnostic sequencing systems. Roche will in turn collaborate with Illumina to complement Illumina’s comprehensive pan-cancer assay TruSight Oncology 500 with new companion diagnostic claims. The financial terms of the deal were not disclosed. Under the IVD terms of the agreement, Roche will develop, manufacture, and commercialize Avenio IVD tests for tissue and blood for use on Illumina’s NextSeq 550Dx. Illumina will continue to sell the NextSeq 550Dx systems and core sequencing consumables.

Q&A column

Q. Does the CAP have recommendations regarding diagnostic criteria for evaluating HER2 in colorectal carcinoma? Read answer.

From the President’s Desk: Our first Leadership Summit

February 2020—Regular readers of CAP TODAY know I believe that it is extremely important for CAP members to become politically active. The upcoming Pathologists Leadership Summit, which will take place May 2–5 in Washington, DC, will give you the opportunity to do so. If you haven’t registered already, I encourage you to consider attending this special event. The Pathologists Leadership Summit is new for the CAP. It is replacing our annual policy meeting focused on government advocacy.

Newsbytes

Drone delivery of lab samples: from progress at WakeMed to interest elsewhere

February 2020—After nearly a year of a drone buzzing through the air to deliver specimens from the Raleigh Medical Park surgery center to the laboratory at the flagship Raleigh campus of WakeMed Health and Hospitals a quarter-mile away, WakeMed is looking to expand its drone program.

Clinical Pathology Selected Abstracts

Blood utilization and transfusion reactions in pediatric patients transfused with platelets

February 2020—Even with advances in donor screening and infectious disease testing, the risk of transfusion-transmitted infections continues to be a concern. The FDA has approved a pathogen-reduction system for single-donor platelets, called Intercept Blood System (Cerus Corp.), to treat thrombocytopenic adult and pediatric patients.

MARKETPLACE

TRENDING